I’m going to write you periodically about ongoing clinical trials , trials soon to come, and other research related issues. I’d say that the ALTERNATE trial is currently my favorite. Eligible patients have palpable tumors > 2cm ER + >70%, Her-2 negative.
There is a 3 arm randomization, as shown, to one of 3 neoadjuvant endocrine arms. Arm 1 is Arimidex (A). Arm 2 is Faslodex (F). Arm 3 is A+F. Repeat cores/blood are due at week 4. Ki67 must be 10 or less to stay on their assigned arm (patients find this very reassuring) to complete 6mos.
I know the schema looks complicated but in reality, its very straightforward and very few patients are switched to chemotherapy.
And I’ve attached a flier for an upcoming Clinical Congress Course “Surgical Oncology for the Rural and Community Surgeon”
Following that you might want to attend PS333 – Clinical Trial: Why and How You Should Incorporate Them into Your Practice Wednesday, October 25, 2017 4:15 PM to 5:45 PM Location : 30B-E.
Gary W. Unzeitig, MD, FACS
Laredo Breast Care
6801 McPherson Rd Suite 106
Laredo, Texas 78041